HALF MOON BAY, Calif., May 13 /PRNewswire/ -- Personalized medicine is changing the face of healthcare. Currently, pharmacogenomic tests can help physicians determine the right dosing schedule for warfarin or to predict the potential for adverse drug reactions. In the near future, health professionals will leverage protein-based biomarkers to predict drug safety and efficacy and to detect disease earlier.
Singulex Inc., a company focused on advancing technologies for early disease detection, today announced that its CEO, Philippe Goix, Ph.D., is chairing a panel on personalized medicine at the Think Tomorrow Today Summit, sponsored by ThinkPanmure. Participants on the panel, entitled "Just for Me: Personalized Medicine," include Michael McKenna, Ph.D., CSO of Tethys Biosciences and Kathryn Phillips, Ph.D., professor of health economics & health services research at UCSF.
"While pharmacogenomics represent much of the current activity in personalized medicine, they are only the tip of the iceberg," said Philippe Goix, CEO of Singulex. "The utility of protein biomarkers could soon eclipse that of pharmacogenomics, allowing much earlier disease detection and also enabling pharmaceutical companies to identify what patient populations will respond to their drug and then to monitor those patients to measure disease regression."
Singulex has pioneered technology that increases the clinical utility of biomarkers using immunoassay technologies. Through collaborations with pharmaceutical and biotechnology companies and academic researchers, the company has shown specifically that the biomarker c Troponin I (cTnI), a validated biomarker for cardiac necrosis, can be detected in healthy people. Singulex can also measure small changes in cTnI levels that indicate stress to the heart, such as during treadmill stress tests, which other technologies cannot do.
About Singulex
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at http://www.singulex.com.
CONTACT: Carolyn Hawley of Porter Novelli Life Sciences, +1-619-849-5375,
chawley@pnlifesciences.com, for Singulex Inc.
Web site: http://www.singulex.com/
